BioNano Genomics, Inc. (BNGO) Posts Q3 Revenue of $2.8M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Bionano Genomics Releases Operating Results for Third Quarter 2018
November 7, 2018 4:01 PM ESTCompleted recent IPO raising $23.7 million in gross proceeds 23% increase in product revenue for the first nine months of 2018
SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced financial results for the three and nine months ended September 30, 2018.
Recent Accomplishments and Business Highlights
Completed an Initial Public Offering in August 2018, raising $23.7 million of gross proceeds (including the... More


